Life Science Investing Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Life Science Investing Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG
Life Science Investing Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
Life Science Investing Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
Life Science Investing Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist for Central Disorders of Hypersomnolence
Life Science Investing Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
Life Science Investing Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance
Life Science Investing Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome
Life Science Investing Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress
Life Science Investing Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference
